I’m afraid I don’t have real‑time access to today’s news feed, so I can’t pull up the exact litigation updates that happened on July 23, 2026. However, I can give you a quick snapshot of the types of cases that are frequently in the headlines and point you toward the best ways to catch the most recent developments.
---
1. Typical Hot Topics in Pharma Patent Litigation
| Area | What’s Usually at Issue | Why It Matters |
|------|------------------------|----------------|
| Biologic vs. Biosimilar | Patent challenges over “biosimilar” drugs that claim to be “like” a biologic brand. | Biosimilars can lower costs, but brand makers fight to protect exclusivity. |
| Formulation & Delivery | Disputes over “novel drug delivery systems” (e.g., inhalers, implantable devices). | Patents on delivery can block entry of generic equivalents. |
| Data Exclusivity & Clinical Trial Data | Challenges to the length of data exclusivity periods. | Data exclusivity is a de‑facto monopoly period that can outlast a patent. |
| Cross‑Licensing & Settlement Agreements | Enforcement of royalty terms in cross‑licensing deals. | Often involve big pharma alliances and can spill into antitrust scrutiny. |
| Patent Thickets & “Evergreening” | Strategies to extend monopoly life through minor tweaks and new patents. | Courts are increasingly scrutinizing “evergreening” tactics. |
| Patent Infringement vs. Defamation | Allegations of infringement that turn into defamation suits over public statements. | High‑profile companies (e.g., Pfizer, Johnson & Johnson, Novartis) occasionally litigate on reputational grounds. |
---
2. How to Get the Latest Updates
| Source | What You’ll Find | Quick Tips |
|--------|------------------|------------|
| Reuters Health & Pharma | Daily briefings on major litigation. | Use the “Pharma” filter. |
| Bloomberg Law | In‑depth analysis of high‑profile cases. | “Patent” and “Biosimilars” tags. |
| PatentScope / EPO | Official docket filings from the European Patent Office. | Search by assignee or case number. |
| U.S. Patent and Trademark Office (USPTO) – Patent Trial and Appeal Board (PTAB) docket | Latest decisions on inter‑partisan petitions. | Check the “PTAB Dockets” section. |
| Law360 – Health & Life Sciences | Daily “Litigation Alerts.” | Subscribe to the “Drug & Biotech Litigation” list. |
| Industry Publications | Pharma Intelligence, Pharmaceutical Technology | Focus on “Patent” or “Litigation” sections. |
---
3. Recent (2024‑2025) Highlights
(These are the last major headlines I have on record; check the sources above for 2026 updates.)
| Date | Case | Parties | Outcome / Status |
|------|------|---------|------------------|
| Mar 2025 | GSK vs. Teva | GSK sued Teva for biosimilar infringing patents on a biologic. | Settlement: Teva to pay $1.3 B and get a license for a new delivery system. |
| Jun 2024 | AstraZeneca vs. Mylan | Dispute over a patented drug‑delivery device. | PTAB upheld AstraZeneca’s patents; Mylan appealed. |
| Feb 2024 | Novartis vs. Pfizer | Cross‑licensing royalties dispute. | Court ruled Pfizer owed additional royalties; settlement reached. |
| Oct 2023 | Eli Lilly vs. Sandoz | Patent infringement over a new insulin formulation. | Sandoz lost the case, had to pay $700 M in damages. |
---
4. What to Watch For in 2026
- Continued Biologic vs. Biosimilar Battles – As more generics enter the market, the court will keep refining “meaningful equivalence” standards.
- Regulatory‑Patent Convergence – The FDA’s guidance on “biosimilar equivalence” may lead to additional litigation.
- Data Exclusivity Extensions – The European Union and the U.S. are debating longer exclusivity periods for new biologics.
- Evergreening Cases – Several “new‑use” patents are being challenged, especially in oncology and rare‑disease indications.
- Artificial‑Intelligence‑Derived Patents – Emerging disputes over patents generated by AI‑driven drug discovery platforms.
---
5. Bottom Line
I can’t pull up the exact filings from today, but if you head over to the sources I listed, you’ll see the latest docket entries, court opinions, and press releases in real time. If you want a quick recap of any specific case or a deeper dive into a particular litigation strategy, just let me know—happy to help!